Key Features of Indian Pharmacopoeia 2026(IP 2026):
Expanded Drugs: IP 2026 added 121 new monographs, totaling to 3,340, strengthening drug quality standards. It expands coverage of Anti-Tubercular medicines, Anti-Diabetic medicines, Anti-Cancer drugs, and Iron and micronutrient supplements used in national programs.
- Monograph is a standard that specifies identity, purity and strength, tests and analytical methods, limits for impurities, and storage and labelling requirements.
Blood Component Standards: 20 monographs for blood components have been introduced for transfusion medicine in line with the Drugs and Cosmetics (Second Amendment) Rules, 2020, to ensure safe blood transfusions and adherence to national regulatory standards.
About Indian Pharmacopoeia(IP): It is the official compendium of drug standards in India and is legally enforceable under the Drugs and Cosmetics Act, 1940. It is published by the Indian Pharmacopoeia Commission (IPC) under the MoHFW. It was published in 1955 for the first time.
- It is the primary reference for quality, safety, and efficacy of drugs and pharmaceuticals in India, regulatory inspections, drug licensing, and manufacturing standards, and laboratories and hospitals for quality control testing.
About Ministry of Health and Family Welfare (MoHFW):
Union Minister – Jagat Prakash (J.P.) Narayanlal Nadda (Rajya Sabha – Gujarat)
Ministers of State (MoS) – Jadhav Prataprao Ganpatrao (Constituency – Buldhana, Maharashtra); Anupriya Patel (Constituency – Mirzapur, Uttar Pradesh, UP)
No comments yet. Be the first!